Author predicts SLS will reach $45-100 by mid-2026 due to GPS Phase 3 AML success and potential buyout.
SLS — LONG Author sets a $45-100 price target by mid-2026 for SLS based on its GPS immunotherapy Phase 3 trial in AML, which he claims is statistically impossible to fail and will become a blockbuster. He also cites a 217M float, hot biotech/immunotherapy sentiment, and potential buyout valuations from $10B to $30B.
GPS at this point is statistically impossible to fail, this is going to be a blockbuster.
This Reddit post, published January 02, 2026, features u/Crew4815162342 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Crew4815162342 · Tickers: SLS